Literature DB >> 12439172

A lack of association between p53 mutations and recurrent nasopharyngeal carcinomas refractory to radiotherapy.

Kai-Ping Chang1, Sheng-Po Hao, Shinn-Yn Lin, Kuo-Chien Tsao, Tseng-tong Kuo, Ming-Hsui Tsai, Chen-Kan Tseng, Ngan-Ming Tsang.   

Abstract

OBJECTIVE: The object of this study was to determine the incidence of p53 mutation in recurrent nasopharyngeal carcinoma refractory to radiotherapy. STUDY
DESIGN: Prospective study.
METHODS: There were 31 patients enrolled in this study between 1995 and 1998. All patients had received radiotherapy but none of them had undergone chemotherapy or local salvage surgery previously.
RESULTS: The p53 status of each tumor was analyzed by polymerase chain reaction and by sequencing of exons 5 to 8 (codons 126-306). Five (16.1%) of 31 patients had mutations in the p53 gene, of which 2 were non-sense mutations, 2 were transition mutations, and 1 was a frameshift deletion mutation. The majority of the p53 mutations were found in exon 5. There is no significant difference in the incidence of p53 mutation compared with that of the previous reports for the primary disease. Based on the clinicopathologic data, there was no specific difference found between these 5 patients and the others.
CONCLUSIONS: This study shows that p53 mutation is an infrequent event and may have no essential role in recurrent nasopharyngeal carcinomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439172     DOI: 10.1097/00005537-200211000-00019

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.

Authors:  Xiaoqin Fan; Yujie Wang; Jian Song; Hanwei Wu; Ming Yang; Lu Lu; Xin Weng; Lusha Liu; Guohui Nie
Journal:  Cancer Biol Ther       Date:  2019-07-16       Impact factor: 4.742

2.  Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression.

Authors:  Xiang Zheng; Jia Wang; Lingyu Wei; Qiu Peng; Yingxue Gao; Yuxin Fu; Yuanjun Lu; Zailong Qin; Xuemei Zhang; Jianhong Lu; Chunlin Ou; Zhengshuo Li; Xiaoyue Zhang; Peishan Liu; Wei Xiong; Guiyuan Li; Qun Yan; Jian Ma
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

Review 3.  Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment.

Authors:  Voon Yee-Lin; Wong Pooi-Fong; Alan Khoo Soo-Beng
Journal:  Mini Rev Med Chem       Date:  2018       Impact factor: 3.862

4.  Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity.

Authors:  Yee-Lin Voon; Munirah Ahmad; Pooi-Fong Wong; Roslina Husaini; Wayne Tiong-Weng Ng; Chee-Onn Leong; David Philip Lane; Alan Soo-Beng Khoo
Journal:  Oncol Rep       Date:  2015-08-05       Impact factor: 3.906

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.